-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$2.5049.7% Upside
Innovid Corp. Frequently Asked Questions
-
What analysts cover Innovid Corp.?
Innovid Corp. has been rated by research analysts at Morgan Stanley in the past 90 days.